News from Eyewire+
Media Bias Ratings
Do you disagree?
Edit bias
Learn more about Media Bias Ratings.
Factuality
Learn more about Factuality Ratings
Reveal Factuality Ratings by upgrading to a Premium account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Ownership
Learn more about Ownership categories
Reveal Ownership Data by upgrading to a Vantage account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Top Eyewire+ News
Ripple Therapeutics Enters Collaboration With Bausch + Lomb

Chester County, Pennsylvania · Chester CountyMALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) will present its latest advances in gene therapy for blindness diseases at NobleCon21, the annual emerging growth equity conference hosted by Noble Capital Markets, the company announced. Dr. Shankar Musunuri, Ocugen’s chairman, CEO and co-founder, is scheduled to deliver a presentation and fireside chat at 1 p.m. ET on Dec. 3 in Presentation Room 2 at Florida Atlantic University’s Executive Education Co…See the Story
Ocugen CEO to Spotlight Gene Therapy Breakthroughs at High-Profile Growth Conference

Technology · United StatesInflammasome Therapeutics has completed subject enrolment for its multicentre Phase II trial of K8, a dual inflammasome inhibitor, aimed at treating geographic atrophy (GA).The post Enrolment concludes for Inflammasome’s K8 Phase II trial for GA appeared first on Clinical Trials Arena.See the Story